# antibody-drug conjugate

Bispecific ADC Combined with PD‑1 Inhibitor Shows Promising Frontline Activity in Extensive‑Stage Small‑Cell Lung Cancer

A phase II trial in China led by Prof. Zhou Caicun reports that the EGFR×HER3 bispecific ADC iza‑bren combined with a domestic PD‑1 inhibitor (Sru‑li) produced a median PFS of 8.2 months and a one‑year OS rate of 85.7% as first‑line therapy for extensive‑stage small‑cell lung cancer. The results are promising compared with historical chemo‑immunotherapy benchmarks but require validation in larger, randomized studies with full safety data.